Full - Drug report, Montelukast, Asthma Treatment. structure function, metabolism, excretion.

Introduction Asthma is a common disorder associated with the respiratory system; it affects one in four primary school children, one in seven teenagers, and one in ten adults in Australia (Bryant et al, 2002). There are many mediators involved in the pathogenesis of an asthma attack, and the severity of the symptoms can vary between individuals. There are several drugs that have been developed to treat the disorder, with differing mechanisms of action such as sympathomimetics, …

…Knorr, B., Franchi, L. M., Bisgaard, H., Vermeulen J. H., LeSouef, P., Santanello, N., Michele, T. M., Reiss, T. F., Nguyen, H and Bratton D. L. (2001) 'Montelukast, a leukotriene receptor agonist, for the treatment of persistent asthma in children aged 2 to 5 years', Pediatrics 108:3, 754-755 Nat. Asthma Council (2002) Leukotriene Receptor Antagonists (LTRAs) - Their Therapeutic Role in Children with Asthma, National Asthma Council, South Melbourne Seale, J. P. (1999) 'Anti-leukotriene drugs - clinical applications', Aust Prescr 22:3, 58-60